Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/18—Feminine contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

• the present invention relates to a composition in the form of a gel for the diffusion of an active principle and intended to be applied to a mucosa and more particularly for applications of vaginal treatments.
• the invention also covers the process for preparing this composition in order to obtain a suitable product.
• the problem of treating sensitive areas such as the mucous membranes is a problem of applying and maintaining the active principles on the area with sufficient durability to ensure the action of these principles, without this causing discomfort for the person being treated.
• the product must be packaged in multidoses or single doses and be very easy to apply to the area since it is difficult to access.
• vaginal route which is the example used to explain the characteristics and advantages of the present invention, without this choice remaining limited to this single mucosa.
• Different drugs can be combined with the gel for topical application.
• a first application could be antifungals.
• Such molecules are packaged in solid forms: tablets, ova or capsules.
• the tablets have a diffuse action which does not allow a targeted action.
• Gels are also known, but these, in contact with the mucosa, remain in the form of a gel and tend to lose their viscosity, which leads to uncomfortable flows for the patients. In addition, the remanence remains low, which limits the action of the active ingredients and / or requires longer treatment. In addition, the packaging of the only commercial product known for the treatment of vaginal yeast infection is of the multidose type with a graduated applicator which is not particularly satisfactory for this type of pathology.
• a second application could be antibiotics for the curative treatment of bacterial vaginosis, for example econazole and / or metronidazole or an antibiotic of macrolide type.
• An excessively pronounced increase in viscosity cannot be envisaged for problems of complexity of application to mucous membranes which are difficult to access.
• the present invention provides a composition which makes it possible to preserve the ease of application of the gels, which ensures good impregnation of the treated mucosa, which has a strong residual effect, which is comfortable for the patient and which allows the diffusion of a wide range of active ingredients.
• all the products for which a local effect is sought are capable of being incorporated into a gel according to the present invention. Mention may be made of decongestants, anti-inflammatories, anti-allergics, analgesics or anti-pruritics, natural hormone replacement products or contraceptives such as estrogen-progestogens or synthetic contraceptives such as danazol.
• the active principle retained is incorporated into a thermoreversible, bioadhesive gel.
• this gel of being liquid at room temperature or at least at very low viscosity, allows diffusion by various means in particular in aerosol by packaging in a bomb with propellant gas or using a pocket valve. This application is carried out under the supervision of medical personnel. The lesional areas are thus reached with precision and the gel, due to its bioadhesiveness, remains on the area long enough for the medicinal principle to take effect.
• thermoreversible gels in particular in patents US-A-4 1 88 373 and CA-A-1 072 41 3.
• polyoxyethylene-polyoxypropylene polymers are used. These gels are used as vectors of drugs to be deposited on mucous membranes.
• thermo-rheological modifications of the gels however, without arriving at solutions as claimed in the present invention.
• this prior art does not focus on the particular applications envisaged and on the possibilities of administration to patients.
• the present invention provides a preparation capable of being sprayed at room temperature for a more targeted application and having a highly bioadhesive character on the mucous membranes.
• - Figure 1 a view of a curve of the viscosity of a preferred composition of the invention compared with the base product, and - Figures 2A and 2B, compared chromatograms of the same composition immediately after manufacture and after passage for one month in an oven at 45 ° C.
• the general composition comprises the combination of a thermoreversible gelling agent, a bioadhesive gelling agent and at least one active principle.
• the thermoreversible nature makes it possible to conserve the gel with a very low viscosity making it possible to consider it as a liquid at room temperature and a viscous form at body temperature.
• the liquid form before application facilitates regular and reproducible distribution on the surface of the mucosa while the more viscous form allows better adhesion to the mucosa by limiting the flow.
• bioadhesive nature makes it possible to improve the contact between the active principle and the mucous membrane, which increases the therapeutic effectiveness and the persistence of the action so as to limit the number of applications and the duration of the treatment by improving compliance. .
• bioadhesive character reinforces the viscosity effect generated by the thermoreversibility of the gel and further limits the possible flows to the point of eliminating them in most cases.
• composition according to the invention which is particularly suitable, is indicated below: - 15% Poloxamer: solubilizing, thickening, thermoreversible gelling agent.
• Carbomer bioadhesive gelling agent.
• An example of a satisfactory commercial product from this family of high molecular weight acrylic acid polymers is Carbopol 5984, the viscosity of which is between 25,000 and 45,000 centipoises.
• micronized econazole nitrate ⁇ 50 ⁇ m, which is a known antimycotic.
• POBMS methyl parahydroxybenzoate
• POBPS propyl
• premix 2 dispersion of the active principle in a volume of water brought to a temperature of the order of 30 to 35 ° C, and - mixing with the deflocculator of the poloxamer, the carbomer and the premixes 1 and 2.
• the order of introduction is of some importance because preferably, the active ingredient is incorporated last, after the poloxamer.
• the latter has solubilizing properties which reduce the propensity of the active principle to form aggregates of particles and therefore to cause inappropriate sedimentation.
• FIG. 1 shows the curve of the results obtained compared concerning the variations of the viscosity as a function of the temperature, variations which are very significant.
• the smoothed curve A is the image of the variations in viscosity of the
• Lutrol used in isolation does not really have thermogelling behavior.
• the amounts of poloxamer capable of producing the desired effects are between 1.0% and 40.0%, more particularly between 5.0% and 20.0%.
• the amounts of carbomer capable of producing the desired effects in association with the poloxamer taken in the amounts indicated above are between 0.1% and 2.0, more particularly between 0.5% and 1.0%.
• Another series of comparative tests consists of carrying out tests on the rabbit eye.
• the composition has a viscosity of 20,000 centipoise, at 30 ° C.
• composition also has a viscosity of 20,000 centipoises, at 30 ° C.
• compositions are applied to the eye of five rabbits, the control preparation on the right eye and the test preparation on the left eye.
• the persistence of the presence of fluorescein is assessed by examining the fluorescence of the eyes of rabbits subjected to UV lighting (254nm).
• Tests have also shown the advantage of a possible addition of a cellulose derivative such as a monocrystalline cellulose marketed under the name “Avicel”, thixotropic agent, or preferably hydroxypropyl methylcellulose, marketed under the name “Methocel E5 premium ".
• a cellulose derivative such as a monocrystalline cellulose marketed under the name “Avicel”, thixotropic agent, or preferably hydroxypropyl methylcellulose, marketed under the name “Methocel E5 premium ".
• a cellulose derivative in synergy with the poloxamer makes it possible to reduce the range of transition and phase temperatures and to very significantly increase the viscosity of the gel during the thermogelling phase, during exposure to heat.
• the suitable quantities vary from 1 to 5% without these limits being barriers to use, but large quantities do not significantly modify the properties, whereas they can on the other hand make the thermoreversible character disappear.
• the preservation is of the order of 5 years in a stable manner, that is to say that the active principle remains in dispersed or solubilized form in the gel.
• the curves in FIGS. 2A and 2B attest to this stability.
• the description which has just been indicated covers an application to the treatment of affections of the vaginal mucosa but the same would be the case for any other mucosa of difficult access.
• the essence of the invention remains the combination of a poloxamer type gelling agent and a product having bioadhesiveness characteristics, in the compositions and the concentrations described ensuring maximum bioadhesiveness.
• the active ingredients capable of being associated with this composition can be of different natures and even be associated within the same composition. It is thus possible to retain antifungals, antibiotics or hormone replacement or contraceptive products natural such as estrogen-progestogens or synthetic contraceptives such as danazol.
• the low viscosity at room temperature makes it possible to use particularly suitable administration means which totally use the low viscosity at room temperature and the high bioadhesiveness.
• administration means which totally use the low viscosity at room temperature and the high bioadhesiveness.
• the product Under medical supervision, for example during a gynecological examination using a speculum, at sight the product can be sprayed or sprayed by the doctor in jets on the mucosa affected by the condition to be treated.
• the gynecologist can thus bring the product directly to the infected area (s).
• the product adhering to the mucosa is at a concentration higher than the MICs (minimum inhibitory concentrations) for a sufficient time to eradicate the vectors responsible for the infection.
• composition according to the invention can also be self-administration.
• the same advantages of the composition according to the invention are found with regard to the low viscosity during application and the high persistence once applied.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Reproductive Health (AREA)
• Gynecology & Obstetrics (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Inorganic Chemistry (AREA)
• Urology & Nephrology (AREA)
• Endocrinology (AREA)
• Diabetes (AREA)
• Pulmonology (AREA)
• Hematology (AREA)
• Rheumatology (AREA)
• Immunology (AREA)
• Pain & Pain Management (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Detergent Compositions (AREA)
• Steroid Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9553244

Family Applications (1)

Country Status (13)

Cited By (1)

Families Citing this family (6)

Citations (4)

Family Cites Families (4)

• 1999
  • 1999-12-14 FR FR9915763A patent/FR2802097B1/fr not_active Expired - Fee Related
• 2000
  • 2000-12-14 ES ES00988913T patent/ES2270895T3/es not_active Expired - Lifetime
  • 2000-12-14 WO PCT/FR2000/003533 patent/WO2001043720A1/fr not_active Ceased
  • 2000-12-14 DE DE60030319T patent/DE60030319T2/de not_active Expired - Lifetime
  • 2000-12-14 DK DK00988913T patent/DK1237537T3/da active
  • 2000-12-14 AT AT00988913T patent/ATE336987T1/de active
  • 2000-12-14 JP JP2001544659A patent/JP2003516957A/ja active Pending
  • 2000-12-14 EP EP00988913A patent/EP1237537B1/fr not_active Expired - Lifetime
  • 2000-12-14 CA CA002394416A patent/CA2394416A1/fr not_active Abandoned
  • 2000-12-14 US US10/149,695 patent/US20030091642A1/en not_active Abandoned
  • 2000-12-14 PT PT00988913T patent/PT1237537E/pt unknown
  • 2000-12-14 AU AU25256/01A patent/AU2525601A/en not_active Abandoned
• 2006
  • 2006-11-16 CY CY20061101679T patent/CY1106249T1/el unknown

Patent Citations (4)

Also Published As

Similar Documents

Legal Events